NCT04668443

Brief Summary

D²EFT-GIC is a substudy of D²EFT study (NCT03017872), a randomised clinical trial of second-line antiretroviral therapies. The goal of D²EFT-GIC is to evaluate a novel tool, the "Graphical Informed Consent" (GIC), within D²EFT. The GIC is designed to supplement the informed consent process with a set of culturally- and gender-adapted illustrations, with an explanatory script for researchers, that complements the mandatory written participant information sheet and consent form. The investigators propose to assess the acceptability and feasibility of this tool from the participants and researchers perspectives. The GIC will be first pre-tested in one or more site(s) - where the informed consent process is challenging because of literacy, language or culture barriers - in 10 prospective participants for D²EFT. If this stage shows there is no negative impact of the GIC on the consent process, the second stage will study the feasibility of implementing the GIC in the usual practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2020

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 16, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

March 22, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

January 11, 2022

Status Verified

January 1, 2022

Enrollment Period

9 months

First QC Date

December 3, 2020

Last Update Submit

January 6, 2022

Conditions

Keywords

Informed consent process

Outcome Measures

Primary Outcomes (1)

  • Proportion of prospective D²EFT participants to whom researchers offered the supplemental GIC during the informed consent process (Stage 2)

    Utilisation (uptake) of the GIC by researchers: number of times researchers offered the supplemental GIC during the informed consent process of D²EFT divided by the total number of prospective participants who underwent informed consent for D²EFT during the substudy period when the GIC is freely available

    Up to 1 year

Secondary Outcomes (3)

  • Proportion of participants who find the illustrations helpful (Stage 1)

    Up to 3 months

  • Proportion of researchers who think there are issues in using the GIC (Stage 1)

    Up to 3 months

  • Proportion of participants who accept to undergo the D²EFT informed consent process with GIC (Stage 2)

    Up to 1 year

Study Arms (2)

Prospective participants in D²EFT study

HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)

Other: Graphical Informed Consent (GIC)

Researchers obtaining informed consent for D²EFT study

Healthcare givers involved in the participant informed consent process of D²EFT

Other: Graphical Informed Consent (GIC)

Interventions

The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.

Prospective participants in D²EFT studyResearchers obtaining informed consent for D²EFT study

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Prospective participants for D²EFT study and researchers obtening the informed consent process.

You may qualify if:

  • Fulfil the eligibility criteria for D²EFT and willing to undertake D²EFT informed consent process;
  • Being able to give a verbal consent for the D²EFT-GIC.

You may not qualify if:

  • Unwilling to comply with the substudy requirements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Human Virology Nigeria (IHVN)

Abuja, Nigeria

Location

Study Officials

  • Mark Polizzotto, MD, PhD

    The Kirby Institute, UNSW

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2020

First Posted

December 16, 2020

Study Start

March 22, 2021

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

January 11, 2022

Record last verified: 2022-01

Locations